

1. IMPORTANT NOTICE

1.1 The Board (Board) and the Supervisory Committee (Supervisory Committee) have reviewed the 2019 T Q R G and have approved the 2019 T Q R G.

1.2 The Board and the Supervisory Committee have reviewed the 2019 T Q R G and have approved the 2019 T Q R G.

1.3 The Board and the Supervisory Committee have reviewed the 2019 T Q R G and have approved the 2019 T Q R G.

1.4 The 2019 T Q R G and have approved the 2019 T Q R G.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 Major financial information

Unit: million RMB

	30 September 2019	31 December 2018	Ratio of change (%)
Total assets	78,569,297,725.65	70,551,361,387.48	11.36
Net assets attributable to equity holders of the parent	30,633,746,877.27	27,977,736,427.49	9.49
	Jan - Sept 2019	Jan - Sept 2018	Period-on-period change (%)
Net assets attributable to equity holders of the parent	2,328,355,784.17	2,087,826,458.74	11.52
	Jan - Sept 2019	Jan - Sept 2018	Period-on-period change (%)
Operating revenue	21,227,618,679.11	18,142,384,871.95	17.01
Net profit attributable to equity holders of the parent	2,063,704,147.99	2,094,152,353.81	-1.45
Net profit attributable to equity holders of the parent (excluding non-controlling interests)	1,722,388,028.34	1,591,668,096.39	8.21
Basic earnings per share (RMB/ share)	7.21	8.00	Decrease of 0.79
Diluted earnings per share (RMB/ share)	0.81	0.83	-2.41
Diluted earnings per share (RMB/ share)	0.81	0.83	-2.41

Notes: In 2019, the Group's total assets increased by 11.36% compared with 2018. The net assets attributable to equity holders of the parent increased by 9.49% compared with 2018. The net assets attributable to equity holders of the parent (excluding non-controlling interests) increased by 11.52% compared with 2018. The operating revenue increased by 17.01% compared with 2018. The net profit attributable to equity holders of the parent decreased by 1.45% compared with 2018. The net profit attributable to equity holders of the parent (excluding non-controlling interests) increased by 8.21% compared with 2018. The basic earnings per share decreased by 0.79 compared with 2018. The diluted earnings per share decreased by 2.41 compared with 2018.

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED*	938,095,290	RMB ordinary shares	938,095,290
HKSCC NOMINEES LIMITED (Note 1)	551,255,448	Ordinary shares	551,255,448
CHINA SECURITIES FINANCE CORPORATION LIMITED*	38,736,157	RMB ordinary shares	38,736,157
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	36,199,707	RMB ordinary shares	36,199,707
NATIONAL SOCIAL SECURITY FUND 113 PORTFOLIO*	28,066,210	RMB ordinary shares	28,066,210
BASIC PENSION INSURANCE FUND 802 PORTFOLIO*	25,824,892	RMB ordinary shares	25,824,892
CENTRAL HONGKONG ASSET MANAGEMENT LTD.*	24,067,700	RMB ordinary shares	24,067,700
NATIONAL SOCIAL SECURITY FUND 110 PORTFOLIO*	15,358,518	RMB ordinary shares	15,358,518
ABU DHABI INVESTMENT AUTHORITY	13,790,532	RMB ordinary shares	13,790,532
CHINA CONSTRUCTION BANK CORPORATION – CHINA-EUROPEAL ENERGY SECURITIES INVESTMENT FUND*	10,198,273	RMB ordinary shares	10,198,273
Details of the shareholding status of the Top 10 unrestricted shareholders	Total	Ordinary shares	3,493,500,000
Details of the shareholding status of the Top 10 unrestricted shareholders	Number of shares	Ordinary shares	3,493,500,000

Note 1: HKSCC NOMINEES LIMITED, a wholly-owned subsidiary of HSBC, is the registered holder of 551,255,448 ordinary shares of the Company, representing 1.37% of the total number of shares of the Company. HSBC is the registered holder of 34,993,500 ordinary shares of the Company, representing 1.00% of the total number of shares of the Company.

Note 2: HONG KONG SECURITIES CLEARING COMPANY LIMITED is a wholly-owned subsidiary of HSBC.

2.3 The shareholding status of the Top 10 shareholders of the Company is as follows:

Registered Capital: RMB 3,493,500,000

Number of shares: 3,493,500,000

(3) Statement of Cash Flow

Unit: million RMB

Statement of Cash Flow				
Items	Jan – Sept 2019	Jan – Sept 2018	Ratio of change	Reasons of changes
Net change in cash and cash equivalents	-2,560,243,375.55	-4,338,289,449.60	40.98%	Mainly due to the increase in cash and cash equivalents from the disposal of subsidiaries and the decrease in cash and cash equivalents from the disposal of subsidiaries and the decrease in cash and cash equivalents from the disposal of subsidiaries.
End of period cash and cash equivalents	47,762,255.60	-31,014,791.25	254.00%	Mainly due to the increase in cash and cash equivalents from the disposal of subsidiaries and the decrease in cash and cash equivalents from the disposal of subsidiaries.

- 3.2 Analysis of the change in cash and cash equivalents
- The 2016 net change in cash and cash equivalents is RMB10,208 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB10,208 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB5 million).

The 2017 net change in cash and cash equivalents is RMB300 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB300 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB300 million).
 - The 2019 net change in cash and cash equivalents is RMB100 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB100 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB100 million).

At the end of the reporting period, the Company had 2,560,000 H Shares outstanding, which were valued at RMB53.54 per share. The Company's share price on the Shanghai Stock Exchange on 30 September 2019 was 0.10% higher than the closing price of RMB53.54 on 19 September 2019.

3. On 27 November 2018, the Company issued 10,000,000 H Shares at a price of RMB53.54 per share, totaling RMB535.4 million. The H Shares were listed on the Shanghai Stock Exchange ("Shanghai Henlius"), and the Company's H Shares were also listed on the Hong Kong Stock Exchange ("Hong Kong Stock Exchange").

On 25 September 2019, the Company issued 1,000,000 H Shares at a price of HK\$49.60 per share, totaling HK\$49.6 million. The H Shares were listed on the Hong Kong Stock Exchange ("Hong Kong Stock Exchange") and the Company's H Shares were also listed on the Shanghai Stock Exchange ("Shanghai Henlius"). The Company's H Shares were valued at HK\$3,208.89 per share on 30 September 2019, which is 53.76% higher than the closing price of HK\$2,090.00 on 19 September 2019.

On 17 October 2019, the Company issued 8,700,000 H Shares at a price of HK\$49.60 per share, totaling HK\$431.6 million. The H Shares were listed on the Hong Kong Stock Exchange ("Hong Kong Stock Exchange") and the Company's H Shares were also listed on the Shanghai Stock Exchange ("Shanghai Henlius"). The Company's H Shares were valued at HK\$210.49 per share on 30 September 2019, which is 53.33% higher than the closing price of HK\$137.00 on 19 September 2019.

3.3 Financial Results

Net Profit

3.4 Financial Results

Net Profit

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Legal Representative: Chen Qiyu

29 October 2019

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Tenthousand Yuan

Items	30 September 2019	31 December 2018
Current assets:		
Cash and cash equivalents	10,307,237,302.85	8,546,521,777.04
Financial assets measured at fair value	1,344,673,568.10	616,123,764.39
Receivables	258,620,513.78	712,510,581.95
Trade receivables	4,463,034,533.86	3,623,640,740.82
Other receivables	471,597,865.70	—
Prepaid expenses	596,927,301.93	472,144,580.30
Other financial assets	577,591,869.92	447,434,579.55
Inventory	9,995,755.01	11,660,016.68
Other current assets	36,917,475.21	19,731,451.25
Intangible assets	3,858,842,830.18	3,287,392,199.46
Non-current financial assets	—	—
Other non-current assets	1,162,820,637.56	—
Other non-current assets	368,970,686.90	295,958,970.62
Other non-current assets	23,410,317,110.78	18,001,727,194.13
Non-current assets:		
Derivative financial assets	117,956,750.00	67,562,000.00
Long-term equity investments	21,198,447,942.66	21,427,527,810.80
Other non-current financial assets	100,986,503.54	126,313,106.69
Other non-current financial assets	2,100,733,208.89	2,505,806,955.75
Fixed assets	7,291,387,236.53	7,083,251,505.14
Construction in progress	2,942,095,697.03	2,039,800,319.91
Right-of-use assets	433,996,758.51	—
Intangible assets	7,873,710,459.21	7,151,343,109.87
Deferred tax assets	2,676,735,574.42	2,040,773,501.88
Goodwill	9,187,137,617.57	8,853,913,413.52
Long-term equity investments	114,180,385.70	95,198,631.30
Deferred tax assets	242,021,035.79	173,134,814.17
Other non-current assets	879,591,445.02	985,009,024.32
Other non-current assets	55,158,980,614.87	52,549,634,193.35
Other non-current assets	78,569,297,725.65	70,551,361,387.48

Consolidated balance sheet (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
Short-term borrowings	7,440,018,220.78	5,607,192,955.63
Bank deposits	266,942,486.20	149,003,072.96
Trade payables	2,233,670,981.77	2,184,280,272.14
Other payables	562,709,265.76	578,701,499.77
Trade receivables	451,969,450.66	478,905,270.26
Other receivables	4,178,903,272.34	3,237,217,890.12
Interest receivable	220,768,148.00	187,344,429.18
Dividends receivable	139,956,011.68	125,420,505.60
Contract liabilities	388,047,456.85	530,896,724.79
Non-current liabilities	2,206,056,772.37	4,929,603,365.34
Other non-current liabilities	1,599,149,293.47	227,445,337.32
Total current liabilities	19,327,467,200.20	17,923,246,388.33
Non-current liabilities:		
Long-term borrowings	8,816,140,333.28	8,630,661,547.43
Bank deposits	5,781,204,728.90	4,039,456,986.21
Long-term payables	307,212,833.42	—
Long-term receivables	252,679,111.96	416,889,805.19
Dividends payable	358,341,043.66	363,489,177.57
Dividends receivable	2,895,818,060.31	2,908,359,008.27
Other non-current liabilities	2,878,227,018.69	2,676,545,098.82
Total non-current liabilities	21,289,623,130.22	19,035,401,623.49
Total non-current liabilities	40,617,090,330.42	36,958,648,011.82
Equity:		
Parent's equity (attributable to parent)	2,562,898,545.00	2,563,060,895.00
Contract liabilities	11,918,086,638.94	10,544,648,359.54
Minority interest	—	1,711,169.00
Other equity	-238,833,703.62	-274,779,732.99
Shareholders' equity	2,373,685,050.45	2,374,999,312.51
Reserves	14,017,910,346.50	12,771,518,762.43
Total equity (attributable to parent and minority interest)	30,633,746,877.27	27,977,736,427.49
Non-current liabilities	7,318,460,517.96	5,614,976,948.17
Total equity (attributable to parent)	37,952,207,395.23	33,592,713,375.66
Total equity (attributable to parent and minority interest)	78,569,297,725.65	70,551,361,387.48

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Deputy Accounting Director:
Chen Zhanyu

Balance Sheet of the Parent Company

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Tens of thousands

Items	30 September 2019	31 December 2018
Current assets:		
Cash and cash equivalents	1,106,498,344.52	850,102,168.54
Financial assets		
Prepaid expenses		
Other receivables	6,407,634,690.21	6,914,735,852.92
Inventory	299,410,098.84	230,691,574.83
Due from related parties	354,609,680.05	307,409,680.05
Intangible assets	—	—
Non-current receivables	2,536,000,000.00	1,625,000,000.00
Other non-current assets	239,000,000.00	158,570,000.00
Total current assets	10,289,133,034.73	9,548,408,021.46
Non-current assets:		
Due to related parties	6,011,804,080.60	5,465,151,645.71
Long-term investments	23,961,991,164.92	22,999,277,541.00
Other non-current assets	37,689,534.30	37,626,487.24
Goodwill	147,179,403.98	184,188,803.45
Financial assets	6,217,807.54	7,158,298.77
Deferred tax assets	2,305,418.41	2,305,418.41
Intangible assets	1,398,139.68	1,840,272.04
Deferred tax liabilities		
Goodwill		
Long-term liabilities		
Deferred tax liabilities		
Total non-current assets	30,168,585,549.43	28,697,548,466.62
Total assets	40,457,718,584.16	38,245,956,488.08

Balance Sheet of the Parent Company (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
Short-term borrowings	3,825,000,000.00	2,959,000,000.00
Trade payables		
Contract liabilities		
Other payables	94,480,035.63	124,637,901.93
Income tax payable	25,239,506.72	43,694,651.68
Other current liabilities	1,715,449,403.09	1,357,247,173.94
Derivative financial instruments	213,542,735.45	172,658,261.16
Other	229,468.00	229,468.00
Non-current liabilities	1,267,088,795.71	3,769,010,861.94
Other	1,304,675,980.01	5,313,103.87
Total	8,231,933,721.16	8,258,903,693.36
Non-current liabilities:		
Long-term borrowings	346,740,000.00	66,740,000.00
Other	5,781,204,728.90	4,039,456,986.21
Long-term payables		
Derivative financial instruments	325,000.00	550,000.00
Other	1,151,018,873.79	1,151,018,873.79
Other		
Total	7,279,288,602.69	5,257,765,860.00
Total	15,511,222,323.85	13,516,669,553.36
Equity:		
Parent's equity	2,562,898,545.00	2,563,060,895.00
Minority interest	14,247,927,508.28	14,231,054,756.04
Other	—	1,711,169.00
Other	-327,370,661.53	-279,100,142.24
Other	1,247,565,522.50	1,247,565,522.50
Other	7,215,475,346.06	6,968,417,072.42
Total	24,946,496,260.31	24,729,286,934.72
Total	40,457,718,584.16	38,245,956,488.08

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of Accounting Department:
Chen Zhanyu

Consolidated Income Statement

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Ten Thousand Yuan

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Total Revenue	7,054,850,058.34	6,283,385,304.74	21,227,618,679.11	18,142,384,871.95
I. Revenue from Operations	7,054,850,058.34	6,283,385,304.74	21,227,618,679.11	18,142,384,871.95
II. Total Expenses	6,709,469,373.75	5,992,960,058.43	19,857,997,730.00	16,934,362,208.60
I. Expenses from Operations	2,937,674,384.28	2,624,459,330.67	8,536,657,487.53	7,570,324,025.58
Taxes	53,919,704.29	65,311,065.96	170,438,628.37	185,482,861.22
Selling Expenses	2,407,588,465.78	2,156,969,593.90	7,406,036,962.51	5,961,359,845.63
General and Administrative Expenses	681,653,157.36	598,132,921.36	1,800,645,744.87	1,608,430,292.39
Research Expenses	440,645,827.79	405,212,249.70	1,290,028,940.00	1,114,194,226.61
Financial Expenses	187,987,834.25	142,874,896.84	654,189,966.72	494,570,957.17
II. Non-Operating Expenses	(356,331,888.84)	(654,189,966.84)	(94,666,399.57)	(2,156,969,957.17)
III. Non-Operating Income	(86,296.84)	(266,844.44)	(662,399.57)	(430,662.39)
IV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
V. Non-Operating Loss	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
VI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
VII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
VIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
IX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
X. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XIV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XVI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XVII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XVIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XIX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXIV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXVI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXVII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXVIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXIX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXIV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXVI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXVII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXVIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XXXIX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XL. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLIV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLVI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLVII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLVIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
XLIX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
L. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LIV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LVI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LVII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LVIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LIX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXIV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXVI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXVII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXVIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXIX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXIV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXV. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXVI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXVII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXVIII. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXIX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXX. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXXI. Non-Operating Profit	(144,414,931.33)	(1,021,285,107.14)	(1,317,456,765.87)	(1,781,293,915.13)
LXXXII. Non-Operating Profit				

Consolidated Income Statement (Continued)

January – September 2019

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating Profit	-9,016,755.16	-122,010,941.32	34,958,479.93	-532,197,468.31
Operating Profit from Continuing Operations	7,142,372.12	-173,180,224.69	35,946,029.37	-571,964,925.72
() Operating Profit from Discontinued Operations	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
1. Cost of Sales	—	—	—	—
2. Selling Expenses	—	—	—	—
3. Cost of Distribution	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
4. Cost of Administration	—	—	—	—
() Operating Profit from Discontinued Operations	6,998,219.31	-176,937,040.20	62,640,198.48	-470,443,011.66
1. Selling Expenses	-27,514,726.87	22,492,035.64	-57,540,529.80	29,149,580.97
2. Distribution Expenses	34,512,946.18	-199,429,075.84	120,180,728.28	-499,592,592.63
Operating Profit from Discontinued Operations	-16,159,127.28	51,169,283.37	-987,549.44	39,767,457.41
II. Total Operating Profit	626,951,292.40	479,073,767.81	2,490,555,469.23	1,806,839,053.77
Total Operating Profit from Continuing Operations	554,726,673.16	360,501,362.79	2,099,650,177.36	1,522,187,428.09
Total Operating Profit from Discontinued Operations	72,224,619.24	118,572,405.02	390,905,291.87	284,651,625.68
III. Earnings				
() Basic Earnings (元/股)	0.22	0.20	0.81	0.83
() Diluted Earnings (元/股)	0.22	0.20	0.81	0.83

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Deputy Accounting Officer:
Chen Zhanyu

Income Statement of the Parent Company

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Ten Thousand Yuan

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating Profit	3,815,974.06	—	5,685,313.69	9,433.96
Less: Operating Expenses	—	—	—	—
Taxes	1,138,885.77	—	2,411,699.94	43,754.06
Selling Expenses	—	—	—	—
General and Administrative Expenses	65,458,328.69	72,278,881.00	136,505,943.90	151,588,516.01
Research Expenses	1,400,270.20	—	2,952,245.60	—
Financial Expenses	24,847,472.18	29,794,031.27	105,319,187.87	78,043,266.55
Impairment Losses	143,806,935.92	120,916,769.27	411,681,720.73	331,017,960.01
Investment Income	110,395,009.96	101,566,901.47	300,636,180.35	266,631,390.40
Assets Impairment	—	—	—	—
Credit Impairment	—	—	—	—
Provision	110,486.49	75,000.00	300,849.09	225,000.00
Income Tax	438,727,482.59	409,853,353.52	1,342,948,533.13	1,328,284,941.99
Impairment Losses	430,736,612.25	389,199,792.25	1,250,403,969.29	1,156,577,651.49
Goodwill Impairment	—	—	—	—
Goodwill Impairment	-14,794,694.59	66,221,631.43	-36,067,868.78	90,531,856.25
Goodwill Impairment	7,349.80	-886.58	7,349.80	-886.58
II. Operating Profit ("—" %)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Provision	—	—	—	—
Less: Provision	—	—	—	—
III. Total Profit ("—" %)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Less: Income Tax	—	—	—	—
IV. Net Profit ("—" %)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
() Net Profit ("—" %)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
() Net Profit ("—" %)	—	—	—	—



Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
Long-term debt	8,630,661,547.43	8,630,661,547.43	
Bonds payable	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provision for doubtful accounts	—	—	
Long-term lease liabilities	—	325,992,167.00	-325,992,167.00
Long-term debt, net	416,889,805.19	398,095,841.52	18,793,963.67
Deferred income taxes	363,489,177.57	363,489,177.57	
Deferred tax assets	2,908,359,008.27	2,908,359,008.27	
Other non-current liabilities	2,676,545,098.82	2,676,545,098.82	
Total non-current liabilities	19,035,401,623.49	19,342,599,826.82	-307,198,203.33
Total liabilities	36,958,648,011.82	37,348,299,890.45	-389,651,878.63
Equity (or shareholders' interests):			
Preferred stock	2,563,060,895.00	2,563,060,895.00	
Common stock	10,544,648,359.54	10,544,648,359.54	
Long-term equity investments	1,711,169.00	1,711,169.00	
Other equity	-274,779,732.99	-274,779,732.99	
Share-based compensation	2,374,999,312.51	2,374,999,312.51	
Retained earnings	12,771,518,762.43	12,771,518,762.43	
Total equity	27,977,736,427.49	27,977,736,427.49	
Non-current liabilities and equity	5,614,976,948.17	5,614,976,948.17	
Total equity (including non-current liabilities)	33,592,713,375.66	33,592,713,375.66	
Total assets	70,551,361,387.48	70,941,013,266.11	-389,651,878.63

Equity (including non-current liabilities):

For 1 January 2019, the Group's total assets, non-current liabilities, and equity were RMB 70,551,361,387.48, RMB 5,614,976,948.17, and RMB 33,592,713,375.66, respectively, compared with RMB 70,941,013,266.11, RMB 5,614,976,948.17, and RMB 33,592,713,375.66, respectively, as of 31 December 2018.

The decrease in total assets, non-current liabilities, and equity is primarily due to the decrease in long-term debt, net, which is related to the repayment of long-term debt. The decrease in long-term debt, net is primarily due to the repayment of long-term debt. The decrease in long-term debt, net is primarily due to the repayment of long-term debt.

Balance Sheet of the Parent Company

Unit: RMB

Items	31 December 2018	1 January 2019	Adjustment
Current assets:			
Cash	850,102,168.54	850,102,168.54	
Accounts receivable	6,914,735,852.92	6,914,735,852.92	
Inventory	230,691,574.83	230,691,574.83	
Due from related parties	307,409,680.05	307,409,680.05	
Non-current receivables	1,625,000,000.00	1,625,000,000.00	
Other receivables	158,570,000.00	158,570,000.00	
Total	9,548,408,021.46	9,548,408,021.46	
Non-current assets:			
Derivative financial assets	5,465,151,645.71	5,465,151,645.71	
Long-term equity investments	22,999,277,541.00	22,999,277,541.00	
Other non-current assets	37,626,487.24	37,626,487.24	
Other non-current receivables	184,188,803.45	184,188,803.45	
Financial assets at fair value through profit or loss	7,158,298.77	7,158,298.77	
Contract assets	2,305,418.41	2,305,418.41	
Intangible assets	1,840,272.04	1,840,272.04	
Total	28,697,548,466.62	28,697,548,466.62	
Total	38,245,956,488.08	38,245,956,488.08	
Current liabilities:			
Short-term debt	2,959,000,000.00	2,959,000,000.00	
Accounts payable	124,637,901.93	124,637,901.93	
Trade payables	43,694,651.68	43,694,651.68	
Other payables	1,357,247,173.94	1,357,247,173.94	
Inventory	172,658,261.16	172,658,261.16	
Due to related parties	229,468.00	229,468.00	
Non-current payables	3,769,010,861.94	3,769,010,861.94	
Other payables	5,313,103.87	5,313,103.87	
Total	8,258,903,693.36	8,258,903,693.36	

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
Long-term debt	66,740,000.00	66,740,000.00	
Bank deposits	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provision for doubtful accounts	—	—	
Deferred income taxes	550,000.00	550,000.00	
Deferred tax assets	1,151,018,873.79	1,151,018,873.79	
Trade payables	5,257,765,860.00	5,257,765,860.00	
Trade receivables	13,516,669,553.36	13,516,669,553.36	
Equity (including minority interest):			
Preferred shares	2,563,060,895.00	2,563,060,895.00	
Common shares	14,231,054,756.04	14,231,054,756.04	
Reserves	1,711,169.00	1,711,169.00	
Other	-279,100,142.24	-279,100,142.24	
Share-based payments	1,247,565,522.50	1,247,565,522.50	
Share-based payments reserve	6,968,417,072.42	6,968,417,072.42	
Trade payables (including minority interest)	24,729,286,934.72	24,729,286,934.72	
Trade receivables (including minority interest)	38,245,956,488.08	38,245,956,488.08	

4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

For 1 January 2019, the Group applied the New Lease Standards and New Financial Instruments Standards retrospectively from the beginning of the reporting period. The impact of the retrospective application of the New Lease Standards and New Financial Instruments Standards is as follows:

The Group's financial statements for 2019 were prepared under the New Lease Standards and New Financial Instruments Standards. The Group's financial statements for 2018 were prepared under the previous standards. The Group's financial statements for 2019 were prepared under the New Lease Standards and New Financial Instruments Standards. The Group's financial statements for 2018 were prepared under the previous standards. The Group's financial statements for 2019 were prepared under the New Lease Standards and New Financial Instruments Standards. The Group's financial statements for 2018 were prepared under the previous standards.

4.4 Audited report

The Group's financial statements for 2019 were audited by the independent member of the audit firm.